Genomics
At Genomics, we are the industry leader in identifying an individualâs absolute risk of disease. Our platform is powered by one of the largest and most unique databases in the world, enabling everyone â from patients and healthcare providers, to partners and employers, to pharma companies and researchers â to make smarter decisions for longer, healthier lives.
- Est. revenue
- $10M–$20M
- Total raised
- $135M
- Latest round
- Series C
- Employees
- 186
Funding & revenue at Genomics
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$10M–$20M
Modeled range, not company-reported
Total capital raised
$135M
16 known investors
Latest round
Series C · $44.6M
Jan 2024
Publicly traded
GENOMICS
Investors
F-PrimeForesite CapitalIP GroupInfinity Investment PartnersInnovate UKInvescoInvesco PerpetualLansdowne PartnersMassMutualOxford Science EnterprisesOxford University InnovationSalicaTanarra CapitalUniversity of OxfordVertex PharmaceuticalsWoodford Investment Management
Growth signals
How fast Genomics is adding people, roles, and audience.
Employees
186
Reported band 51-200
Open roles
1
-0.7% year over year
LinkedIn followers
22.3K
+41.6% year over year
Headcount change
- MoM
- -2.1%
- QoQ
- +0.5%
- 6mo
- -2.1%
- YoY
- -4.6%
- 2yr
- +23.2%
-4 people
+1 people
-4 people
-9 people
+35 people
Team composition
Where Genomics concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research5228%
- Engineering2614%
- Business Development2312%
- Information Technology148%
- Healthcare Services95%
- Operations84%
- Finance63%
- Administrative63%
By region
- United Kingdom127
- England, United Kingdom122
- London Area, United Kingdom51
- Greater London42
- Greater Oxford Area29
- Oxford23
Inside Genomics
What the business focuses on, where it operates, and how employees rate it.
Specialties
genomicsmachine learningdrug discoveryPrecision Healthlife sciences
Categories
BiopharmaBiotechnologyGeneticsHealth CareLife ScienceMedicalTherapeuticsWellnessBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
PRIVATE
Offices
- 50-60 Station Road, Cambridge, England, CB1 2JH, GB
- SPACES, 555 S Mangum St Suite 100, Durham, North Carolina, 27701, US
- King's Cross Road, London, England, GB
Competitors
Companies in the same market as Genomics.
https://e-nios.comhttps://www.nhsx.nhs.uk/https://www.engenome.com/#request-a-demohttps://phasegenomics.comhttp://www.interpretomics.cohttp://humanscape.iohttps://www.actgenomics.comhttp://www.genomemedical.comhttp://www.characterbio.comhttps://premierconsulting.comhttp://www.avesthagen.comhttp://www.minervakrm.comhttp://www.genowis.comhttps://www.genomenon.comhttp://www.veritasint.comhttps://pangenomic.com
Genomics in the news
Recent coverage picked up alongside the firmographic refresh.
- 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Sep 2026
- Artificial Intelligence (AI) in Biotechnology Market Size to Exceed USD 31.87 Billion by 2035 Rising Demand for Faster Drug Discovery and Precision Medicine
Jun 2026
- The Genetics Revolution, Made Real: Professor Sir Peter Donnelly, Genomics
Jun 2026
- Editorial: Plant responses to abiotic stress: unraveling complex mechanisms through genomics and physiology
Jun 2026
- Hartwig Medical Foundation and Ultima Genomics Expand Collaboration to Advance Whole-Genome Sequencing in Oncology Care
Jun 2026
- 10x Genomics acquires Proteintech Genomics to enhance single cell proteomics capabilities.
Jun 2026
Jobs
1
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 26, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Genomics, you can claim this page to manage and enhance it.